| Dr David Michael Henzler, MD | |
|
1100 E Dimond Blvd, Anchorage, AK 99515-2010 | |
| (907) 565-6000 | |
| (907) 565-6001 |
| Full Name | Dr David Michael Henzler |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 33 Years |
| Location | 1100 E Dimond Blvd, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063588184 | NPI | - | NPPES |
| 1727366 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 114232 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Alaska Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Neurology Center Llc | 2163512328 | 7 |
News Archive
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.
NurseWise, a national multilingual nurse advice and health education provider, has moved its El Paso Clinical Care Center operations into a larger space to accommodate the company's continued growth and commitment to increasing the number of individuals it serves.
The World Health Organization (WHO) said on Tuesday that there was no chance the agency would attempt to vaccinate Yemen against cholera due to the fact that the disease has spread so widely there that such an effort would be fruitless. This is a U-turn on a decision made by the organization a month ago. On June 15th this year, the WHO had decided to send one million doses of cholera vaccine to Yemen in collaboration with some other partners. This was following a request from Yemen's internationally recognized government. This new decision revokes the earlier plans.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 2 days ago
| Entity Name | Alaska Neurology Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235310954 PECOS PAC ID: 2163512328 Enrollment ID: O20071212000483 |
News Archive
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.
NurseWise, a national multilingual nurse advice and health education provider, has moved its El Paso Clinical Care Center operations into a larger space to accommodate the company's continued growth and commitment to increasing the number of individuals it serves.
The World Health Organization (WHO) said on Tuesday that there was no chance the agency would attempt to vaccinate Yemen against cholera due to the fact that the disease has spread so widely there that such an effort would be fruitless. This is a U-turn on a decision made by the organization a month ago. On June 15th this year, the WHO had decided to send one million doses of cholera vaccine to Yemen in collaboration with some other partners. This was following a request from Yemen's internationally recognized government. This new decision revokes the earlier plans.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Michael Henzler, MD 1100 E Dimond Blvd, Anchorage, AK 99515-2010 Ph: (907) 565-6000 | Dr David Michael Henzler, MD 1100 E Dimond Blvd, Anchorage, AK 99515-2010 Ph: (907) 565-6000 |
News Archive
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.
NurseWise, a national multilingual nurse advice and health education provider, has moved its El Paso Clinical Care Center operations into a larger space to accommodate the company's continued growth and commitment to increasing the number of individuals it serves.
The World Health Organization (WHO) said on Tuesday that there was no chance the agency would attempt to vaccinate Yemen against cholera due to the fact that the disease has spread so widely there that such an effort would be fruitless. This is a U-turn on a decision made by the organization a month ago. On June 15th this year, the WHO had decided to send one million doses of cholera vaccine to Yemen in collaboration with some other partners. This was following a request from Yemen's internationally recognized government. This new decision revokes the earlier plans.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
› Verified 2 days ago
Daniel Gregory Allen, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 673 Medical Group, Jb Elmendorf-richardson, Anchorage, AK 99506 Phone: 907-580-2181 | |
Robert D Wald, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2605 Denali St, Ste 203, Anchorage, AK 99503 Phone: 907-677-9253 Fax: 907-272-1553 | |
Dr. Sheila Joyce Clark, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 207 E Northern Lights Blvd, Ste 111, Anchorage, AK 99503 Phone: 907-272-1892 Fax: 907-272-0962 | |
Dr. Karen Jackman, M.D Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1675 C St, Suite 117, Anchorage, AK 99501 Phone: 907-274-8281 Fax: 907-274-4055 | |
Dr. Steven Edward Koehl, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-2181 | |
Dr. Cathleen E Marshall, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3340 Providence Dr Ste A565, Anchorage, AK 99508 Phone: 907-212-2321 Fax: 907-212-8499 |